Striverdi Respimat From Boehringer Ingelheim Promeco

Sat, 09/05/2015 - 12:23

Chronic obstructive pulmonary disease (COPD) affects 8% of the Mexican population and kills 21,000 Mexicans every year. The National Institute of Respiratory Diseases (INER) predicts that this disease will become the third mortality cause in Mexico by 2020. COPD is characterized by a progressive breakdown of lung tissue by an inflammatory response after exposure to irritants. The two main risk factors for this disease are smoking and exposure to coal or wood smoke, making this disease especially prevalent in developing countries. COPD’s main symptoms include respiratory problems, wheezing, coughing, and chest tightness, and can be fatal if left untreated.

Striverdi Respimat is a highly selective long-acting beta-2 adrenergic agonist (LABA) developed specifically to treat COPD. This drug mimics the effect of epinephrine at beta- receptorsreducingtheinflammationresponseinthelung by relaxing the bronchi thus permitting the increase of air flow. Unlike other bronchodilators, it can be used daily over prolonged periods of time as it has very few and mild adverse effects.

Developed by Boehringer Ingelheim, Striverdi Respimat was first approved for use in the UK, Denmark, and Iceland in 2013. In July 2014 it was approved by the FDA for use in the US and it was approved by COFEPRIS in March 2015.